Wardle J, Armitage J, Collins R, Wallendszus K, Keech A, Lawson A
Imperial Cancer Research Fund, University College London.
BMJ. 1996 Jul 13;313(7049):75-8. doi: 10.1136/bmj.313.7049.75.
To evaluate the effects on mood of a substantial and prolonged reduction in total cholesterol concentration.
Randomised placebo controlled comparison of patients who had been allocated to receive simvastatin 20 mg or 40 mg daily versus those allocated matching placebo in a ratio of 2:1. Follow up at an average of 152 weeks after randomisation.
Men and women aged between 40 and 75 years at entry with blood total cholesterol of 3.5 mmol/l or greater, who were considered to be at higher than average risk of coronary heart disease based on medical history.
The shortened profile of mood states questionnaire, reported use of psychotropic medication, and symptoms possibly related to mood.
Simvastatin reduced total cholesterol by 1.9 mmol/l (26.7%) at the time of follow up. Among all 621 patients randomised to simvastatin (414 patients) or placebo (207 patients) there were no significant differences in the use of psychotropic medication or in reports of symptoms possibly related to mood. Of these patients, 491 (334 simvastatin, 157 placebo) completed the mood questionnaire, and there were no significant differences between the treatment groups in total or subscale scores, even when patients with low baseline cholesterol concentrations or elderly subjects were considered separately.
These results do not support the hypothesis that treatment to lower cholesterol concentration causes mood disturbance.
评估总胆固醇浓度大幅且持续降低对情绪的影响。
随机安慰剂对照比较，将患者按2:1的比例分为每日接受20毫克或40毫克辛伐他汀组与接受匹配安慰剂组。随机分组后平均随访152周。
入组时年龄在40至75岁之间、血液总胆固醇为3.5毫摩尔/升或更高的男性和女性，根据病史判断其冠心病风险高于平均水平。
情绪状态简表问卷、精神类药物的使用报告以及可能与情绪相关的症状。
随访时辛伐他汀使总胆固醇降低了1.9毫摩尔/升（26.7%）。在随机分配至辛伐他汀组（414例患者）或安慰剂组（207例患者）的所有621例患者中，精神类药物的使用或可能与情绪相关的症状报告方面无显著差异。这些患者中，491例（334例辛伐他汀组，157例安慰剂组）完成了情绪问卷，即使分别考虑基线胆固醇浓度低的患者或老年患者，治疗组在总分或分量表得分上也无显著差异。
这些结果不支持降低胆固醇浓度的治疗会导致情绪障碍这一假说。
